RESCON USA SUMMIT 2025

Inhalation & RESpiratory Drug Delivery | CONnected Devices

5-6 NOVEMBER 2025

Hyatt Regency San Francisco

San Francisco, California, USA

DIAMOND SPONSORS

Harro Höfliger

GOLD SPONSORS

Suttons Creek
The Device Team for Pharma
A BlueRidge Life Sciences Company

Ventura
SOLUTIONS

SILVER SPONSORS

Catalent®

Malvern Panalytical

micromeritics®

SciAps

a powerful combination

ATS American Thoracic Society

MEDIA PARTNERS

Medhealth Outlook

MEDtube
sharing medical knowledge™

ON drugDELIVERY

JOURNAL OF Aerosol Medicine and Pulmonary Drug Delivery
Mary Ann Liebert, Inc. publishers

PHARMA network magazine

OINDP news
Orally inhaled and nasal drug products

BioPharma Asia
The Journal for Asia's Pharmaceutical and Biopharmaceutical Industry

KC World With Science
www.kindcongress.com

PHARMACIRCLE™

RESCON—
—SUMMIT

RESCON Summit 2025 is the leading strategic event for senior executives driving innovation in inhalation and respiratory drug delivery. Taking place on November 5–6, 2025, in San Francisco, the summit brings together global leaders from pharma, biotech, and device industries to explore the latest trends, technologies, and business strategies shaping the future of inhaled therapeutics.

This year's program focuses on high-impact innovations across the full development spectrum — from small molecules and LNPs to smart inhalers, AI-powered design, and digital health integration. With a strong emphasis on commercial viability, regulatory navigation, and partnership building, RESCON Summit 2025 is designed for decision-makers seeking actionable insights and meaningful connections in this rapidly evolving field.

EPM Group Executive Summary

WHO You Will Meet

50+
Attendees

20+
Speakers

RATIO

Bio/pharmaceutical manufacturing **65:35** Vendor/Solution Providers

Company Size of Attendees



- 1000+ employees
- 300-999 employees
- 50-299 employees
- less than 49 employees

Job Title of Attendees



- C-level
- SVP/VP
- Snr Director/Director
- Snr Manager/Manager

Attendee Company Annual Turnover



- 1 Billion
- $500-999Million
- $50-499 Million
- <50 Million

HOW You Will Benefit

x1000+

Relive the conference. Full access to documentation, footages and videos.

x10+

'Hours of Networking. Forge new professional contacts.

x20+

Case Studies Analysis

Companies Attending our events

FEEDBACK

94%
RATED EVENT
★★★★★

Quality of the speakers
Sharing of the best practices
Spectrum of industries
Intimate atmosphere

98%
WOULD RECOMMEND THE EVENT TO COLLEAGUES

Learn
The Key Practical Points

1. Next-Generation Inhalation & Nasal Delivery Platforms

Gain exposure to the latest in non-invasive drug delivery systems, including soft mist inhalers, nasal powders, and epithelial delivery routes, aiming to eliminate syringes and expand therapeutic access.

2. Formulation Innovation: From Nanocarriers to Combination Therapies

Explore formulation strategies for inhalable nanocarriers, microparticles, and combination products, optimizing lung targeting, therapeutic efficacy, and stability.

3. Dry Powder Inhalers: Performance, Usability & Testing

Understand how engineering design, realistic testing models, and patient-centric considerations impact the real-world performance and acceptance of DPIs.

4. Predictive Preclinical Models & Translational Development

Discover integrated approaches combining human ex vivo and in vivo data to enhance the safety, efficacy, and predictivity of respiratory drug development.

5. Digital Health Integration & Smart Device Innovation

See how digital inhalers, remote monitoring, and connected health platforms are shaping the future of adherence tracking, clinical insights, and patient engagement.

6. Regulatory Strategy for Inhaled Combination Products

Navigate FDA and EMA pathways for complex inhaled combination products, including considerations for nebulized gene therapies and evolving environmental standards.

7. Sustainable Design & Green Propellant Transition

Learn how the transition to low global warming potential (GWP) propellants and eco-conscious design is reshaping the respiratory device landscape.

8. Health Economics & Real-World Evidence in Respiratory Disease

Analyze how open and closed claims data, cost-of-illness studies, and economic modeling inform access strategies for rare and chronic respiratory conditions.

9. Patient-Centric Innovation in Inhaled Therapeutics

Examine how usability studies, connected technologies, and human factors research drive more intuitive and effective inhalation therapies tailored to patient needs.

10. Emerging Trends in Inhaled Biologics & Airway Remodeling

Understand scientific advancements in airway mucosal remodeling, aerosol therapy, and the potential of inhaled biologics and ions for systemic and localized effects.

Meet
The Speakers

Jeffry Weers

Independent Consultant at Aerofluor Pharma Consulting

Dan Beach

Sr. Applications Team Lead at Malvern Panalytical



Irene Rossi

Respiratory Sciences Expert at Harro Höfliger

Sarah Mollo

Principal Consultant at Suttons Creek

Andy Clark

Independent pulmonary consultant

Stephen Pham

Senior Vice President, Product Development at Avalyn Pharma Inc.

Bernhard Müllinger

General Manager, COO at Resyca

Gur Jai Pal Singh

Chief Scientific Advisor at BBSG Pharm Associates

Vivek Gupta

Scientific Co-founder at PulmoSIM Therapeutics

C. Vivek Lal

Founder & Executive Chairman at Alveolus Bio

Ulf Krueger

Chief Executive Officer at PULMOTREE

Charles Ventura

Chief Executive Officer at Ventura Solutions

Jim Fink

Chief Science Officer at Aerogen Pharma

Carolyn Berg

Vice President, Business Development at Catalent Pharma Solutions

Armin Braun

Division Director of the Preclinical Pharmacology and Toxicology at Fraunhofer ITEM

John Patton

Senior Strategic Advisor at Kindeva Drug Delivery

Katharina Schwarz

Head Inhalation and Aerosol Sciences at Fraunhofer Institute for Toxicology and Experimental Medicine

Teresa Carvajal

Faculty Member, Professor at the Department of Agricultural and Biological Engineering at Purdue University

David Edwards

Founder Sensory Cloud, Adjunct Professor Johns Hopkins Medical School, Associate School Engineering Harvard University

Loy Britto

Chief Executive Officer at Healthy Airways LLC

Scientific Agenda

DAY 0 TUESDAY, NOVEMBER 4TH

6:00PM - 8:00PM	Pre-Conference Cocktail Reception at Regency Hotel San Francisco

DAY 1 WEDNESDAY, NOVEMBER 5TH

8:00AM	Conference Registration
8:25AM	RESCON Summit Opening Speech

Morning Chairperson: Irene Rossi,Harro Höfliger

Session 1: Next-Generation Nasal and Inhaled Drug Delivery Systems

8:30AM - 9:00AM	**Eliminate the syringe with epithelial delivery: Inhaled/ nasal and intradermal vaccines delivery systems** John Patton, Senior Strategic Advisor at Kindeva Drug Delivery
9:00AM - 9:30AM	**Metered Dose Inhalers Transition to Low Global Warming Propellants: Product Development, Regulatory Complexities, and Paths Forward in Comparison with the Earlier Substitution of Ozone Depleting Gases with Ozone-Friendly Propellants** Gur Jai Pal Singh, Chief Scientific Advisor at BBSG Pharm Associates
9:30AM - 10:00AM	**Emerging Trends in Nasal Drug Development and Delivery** Carolyn Berg, Vice President, Business Development at Catalent Pharma Solutions
10:00AM - 10:30AM	**Speed Networking**
10:30AM - 11:00AM	**Morning Coffee Break & Sponsor Presentations**
11:00AM - 11:30AM	**Transnasal pulmonary aerosol delivery - Enabling effective therapy from premature infants to adults** Jim Fink, Chief Science Officer at Aerogen Pharma

Session 2: Combination Products & Delivery Systems: Regulatory, Technical, and Environmental Pathways

11:30AM - 12:00PM	**Combination Products and Nebulizers: Matching Therapy to Technology** Sarah Mollo, Principal Consultant at Suttons Creek

12:00PM - 12:30PM	**One Risk File for All - Breaking Silos and Real Alignment for Combination Products** Charles Ventura, Chief Executive Officer at Ventura Solutions
12:30PM - 1:00PM	**Challenges and Solutions in Droplet Size Distribution Measurements for OINDP Product Development and Quality Control** Dan Beach, Sr. Applications Team Lead at Malvern Panalytical
1:00PM - 2:00PM	Lunch Break

Afternoon Chairperson: Carolyn Berg, Catalent Pharma Solutions

Session 3:
Formulation and Delivery Innovations in Inhaled and Nasal Therapeutics

2:00PM - 2:30PM	**Engineering Dry Powders for Respiratory Delivery: Current and Future Paradigms** Irene Rossi, Respiratory Sciences Expert at Harro Höfliger
2:30PM - 3:00PM	**Novel Approaches for Inhaled Combination Therapeutics** Vivek Gupta, Scientific Co-founder at PulmoSIM Therapeutics
3:00PM - 3:30PM	**The REACH Trial — Toward a first-line treatment of refractory chronic cough** **David Edwards, Founder, Sensory Cloud; Adjunct** Professor, Johns Hopkins Medical School; Associate, Harvard School of Engineering
3:30PM - 4:00PM	**Soft Mist Delivery: Unlocking New Possibilities for Intranasal and Inhaled Drug Products** Bernhard Müllinger, General Manager, COO at Resyca
4:00PM - 4:30PM	**Afternoon Coffee break**
4:30PM - 5:30PM	**Panel Discussion:** "Innovating for Impact: Aligning Devices, Formulations, and Clinical Needs in Inhalation Therapy" • Integration of device engineering and formulation strategies to improve therapeutic outcomes • Role of clinically relevant testing and real-world use cases in inhaler design • Emerging technologies driving innovation in inhaled combination therapeutics **Panelists:** • John Patton, Kindeva Drug Delivery • Jeffry Weers, Aerofluor Pharma Consulting • Andy Clark, Independent Pulmonary Consultant • Vivek Gupta, PulmoSIM Therapeutics • Jim Fink, Aerogen Pharma Moderated by Carolyn Berg, Catalent Pharma Solutions

5:30PM	End of the RESCON Summit 1st day
7:30PM - 9:30PM	RESCON Summit: Conference Dinner at Regency Hotel San Francisco

DAY 2 THURSDAY, NOVEMBER 6TH

8:25AM	**Opening of the RESCON Summit 2nd day**

Morning Chairperson:
Bernhard Müllinger, Resyca

Session 4: Optimizing Dry Powder Inhalers: Design, Testing & Patient-Centered Performance

8:30AM - 9:00AM	**Critical Parameters for DPI Product Performance: Framing Future of Work Considerations Through Patient-Centric Considerations** Teresa Carvajal, Faculty Member, Professor at Purdue University
9:00AM - 9:30AM	**Design of Dry Powder Inhalers to Improve Patient Outcomes: It's Not Just About the Device** Jeffry Weers, Independent Consultant at Aerofluor Pharma Consulting
9:30AM - 10:00AM	**Realistic, clinically relevant, testing of dry powder inhalers** Andy Clark, Independent Pulmonary Consultant

Session 5: Translational Models & Preclinical Development

10:00AM - 10:30AM	**Translational preclinical development of respiratory drugs using an integrated approach combining human ex vivo and animal in vivo data for optimal predictivity of safety and efficacy.** Armin Braun, Division Director, Preclinical Pharmacology and Toxicology at Fraunhofer ITEM
10:30AM - 11:00AM	**Morning Coffee Break**
11:00AM - 11:30AM	**Predictive Platforms for Early Dose Assessment and Device Alignment in Inhaled Therapeutics** Katharina Schwarz, Head, Inhalation and Aerosol Sciences at Fraunhofer Institute for Toxicology and Experimental Medicine
11:30AM - 12:00PM	**Integrated Real Breathing Profiles to Optimize Lung Deposition Modelling for Clinical Development** Ulf Krueger, Chief Executive Officer at PULMOTREE

Session 6: Digital Health in Inhalation: From Connected Devices to Clinical Integration

12:00PM - 12:30PM

Inhalation Meets Innovation: Monitoring Adherence with Digital Nebulizers
Stephen Pham, Senior Vice President, Product Development at Avalyn Pharma Inc

12:30PM - 1:00PM

Connected Digital Respiratory Therapeutics: Evolution, Clinical Integration, and Future Direction
Loy Britto, Chief Executive Officer at Healthy Airways LLC

1:00PM - 2:00PM

Lunch Break

2:00PM - 3:00PM

Panel Discussion:
Building Smarter Respiratory Platforms: Integration Across Devices, Data & Development

• How the convergence of device platforms, digital tools, and real-world data is reshaping inhalation product design and clinical deployment

• Opportunities and challenges in aligning combination product strategy with user behavior, adherence insights, and regulatory documentation

• Practical strategies to reduce development silos and connect technology selection with long-term therapeutic and commercial value

Panelists:
• Stephen Pham, Avalyn Pharma Inc

• Bernhard Müllinger, COO at Resyca

• Sarah Mollo, Suttons Creek

• Charles Ventura, Ventura Solutions

• Loy Britto, Healthy Airways LLC

Moderated by Ulf Krueger, Chief Executive Officer at PULMOTREE

3:00PM

Closing Remarks & End of RESCON Summit USA 2025


ONE WAY

Biographies

Jeffry Weers Independent Consultant at Aerofluor Pharma Consulting

Accomplished pharmaceutical professional with more than 35 years of experience in the design and development of novel drug delivery systems from initial concept through regulatory approval. Innovator with extensive patent portfolio and publication record on novel formulations, treatments, and delivery technologies for the administration of small molecules, biologics, and combination products. Proven track record in assembling and leading multidisciplinary teams to drive innovation. Jeff has published more than 100 peer reviewed papers (h-index = 58), has authored several book chapters, and spoken at many national and international meetings. He is a prolific inventor with 70 issued US patents and more than 300 patents worldwide.

Dan Beach Sr. Applications Team Lead at Malvern Panalytical

Dan Beach holds a BS in Biochemistry and a Master's in Business Administration. Prior to joining Malvern Panalytical, Dan worked at a CMO focusing on method development and validation as well as working in pre-clinical R&D for a large pharmaceutical company. Since joining Malvern Panalytical, he has held the role of Field Application Scientist as well as being the Team Leader for the Small Molecule Pharmaceuticals group. His background in small molecule drug development and method validation provides unique perspective while supporting laser diffraction and automated imaging.

Irene Rossi Respiratory Sciences Expert at Harro Höfliger

As Harro Höfliger's Expert in Respiratory Science, Irene supports the team and her clients on product development and respiratory drug delivery matters. She is also part of the INTO technical team together with experts from DFE Pharma and Sterling. Irene obtained a MSc in 2014 and a PhD in Drugs, Biomolecules and Health Products at the University of Parma (Italy) in 2019. In the same year she joined Nanopharm, An Aptar Pharma Company (UK) where she covered different roles. Most recently, she was leading a group focused on the development and characterization of new formulation technologies for OINDP products comprising both small and large molecules.

Sarah Mollo Principal Consultant at Suttons Creek

Sarah has 10 years of experience in the medical device and combination product space, including 6 years at the FDA as a Product Jurisdiction Officer and Policy Analyst within CDRH, as well as several years as a Reviewer and Team Leader for injection devices. She brings expertise in regulatory strategy, with a particular focus on drug delivery devices and the unique challenges of combination products. While at the FDA, Sarah served as a key point of contact for external stakeholders, guiding industry sponsors through FDA expectations and complex regulatory issues. She also represented the Agency at national conferences, speaking on topics such as combination product regulation, policy development, and review considerations.

Andy Clark Independent pulmonary consultant

Dr. Andy Clark is currently an independent pulmonary consultant. He helped found the Aerogen Pharma Corporation in 2015 and served as President and Managing Director until 2024. From 2009 to 2014 he was Site Head and Chief Technical Officer for Novartis Pharmaceuticals. Prior to which he was Chief Technical Officer for Nektar Therapeutics and Respira Therapeutics, he also served as Managing Director of Bradford Particle Design. He moved to California in 1992 to lead a pulmonary protein delivery group at Genentech Inc. During this time Andy made major contributions to some of the industries' most innovative products; high dose inhaled Chromones (the first high dose pMDI and dry powder inhaler), Pulmozyme (the first inhaled protein), Exubera (the first inhaled systemic protein), TobiPodhaler (the first dry powder inhaled antibiotic).

Stephen Pham Senior Vice President, Product Development at Avalyn Pharma Inc.

Stephen Pham, Ph.D., is Senior Vice President, Product Development of Avalyn Pharma, Inc. Dr. Pham has over 27 years of industry experience in inhalation and ophthalmic products. Prior to joining Avalyn, Dr. Pham served as a full-time consultant for Sunovion Pharmaceuticals where from Phase 2 through NDA submission and review, Dr. Pham was responsible for Lonhala® Magnair® product development (glycopyrrolate inhalation solution for maintenance treatment of COPD). Prior to Sunovion, he was Senior Director at Elevation Pharmaceuticals where he was responsible for Lonhala Magnair CMC until the Sunovion acquisition in 2012. Previously at Dey Laboratories (now Mylan), Dr. Pham was an inventor of Perforomist® (formoterol fumarate inhalation solution for maintenance treatment of COPD) and responsible for its development and approval.

Bernhard Müllinger General Manager, COO at Resyca

Bernhard Müllinger is General Manager and COO of Resyca BV, focused on soft mist inhalers and nasal spray platforms for drug-device combination products. With over 30 years of experience in aerosol drug delivery, he has worked across therapeutic areas such as asthma, vaccination, and pulmonary hypertension. His expertise includes device engineering, deposition modeling, and the development of drug-device combination products. He previously held senior roles at Vectura, Activaero, and Inamed CROs, and serves on the board of the International Society for Aerosols in Medicine (ISAM).

Gur Jai Pal Singh Chief Scientific Advisor at BBSG Pharm Associates

Dr. Gur Jai Pal Singh is the Chief Scientific Advisor at BBSG Pharm Associates since June 2023. Before that he served as a Senior VP and headed a Pharma Company's Respiratory Centre of Excellence – providing end-to-end hand-on leadership for state-of-the-art development of inhalation drug products. Under his leadership, several orally inhaled products have been successfully developed for the US, EU, and other geographies. Before coming to leadership roles in the private industry, Dr Singh had a 15-years tenure at the US FDA with designation of Senior Expert for Orally Inhaled and Nasal Drug Products (OINDP) – making key contributing to the Agency development of guidelines for OINDP.

Vivek Gupta Scientific Co-founder at PulmoSIM Therapeutics

Dr Vivek Gupta is an associate professor of industrial pharmacy at College of Pharmacy & Health Sciences. Dr Gupta's is an experienced pharmaceutical researcher with interests in developing novel therapies for respiratory disorders. His expertise lies in the fields of novel drug discovery and repurposing, and non-invasive delivery of small and macromolecules via oral and inhalation routes. He also has significant research interest in the fields of pharmaceutical scalability, and nano-repurposing. Diseases of interest include lung cancer, pulmonary fibrosis, pulmonary hypertension, and mesothelioma. Dr. Gupta's research group has published >90 high-impact publications in peer reviewed journals. Multiple technologies and therapies developed by Dr. Gupta's group have been patented and are at various stages of preclinical/clinical development.

C. Vivek Lal Founder & Executive Chairman at Alveolus Bio

Dr. C. Vivek Lal, M.D. is a physician scientist, innovator and entrepreneur. He is the Clinical Director of Innovation at The Marnix Heersink Institute of Biomedical Innovation, Professor and the Director of Pulmonary Microbiome Lab at University of Alabama at Birmingham (UAB). Dr. Lal is the Founder and CEO of ResBiotic Nutrition, Inc., a company that makes science backed wellness supplements. He is also the founder of Alveolus Bio, Inc., a platform biotech company which does FDA approved pulmonary drug development & Urgent Care for Children, a Southeast US based urgent care chain headquartered in AL. After medical school and residency training, Dr. Lal completed his clinical fellowship and research fellowship at University of Texas at Southwestern, Dallas, TX, followed by an executive program in Drug and Device Development from Massachusetts Institute of Technology (MIT).

Ulf Krueger Chief Executive Officer at PULMOTREE

Ulf Krueger has dedicated his entire career to aerosol medicine, combining deep expertise in combination products with an innovative entrepreneurial vision as the founder and CEO of PULMOTREE, a Munich-based company that specializes in developing cutting-edge technologies for targeted pulmonary drug delivery. He is a trained biomedical engineer with extensive experience in the development of respiratory drug delivery systems. His career spans roles in research and development, as well as management positions, where he contributed to the successful commercialization of products at companies such as PARI and Vectura.

Charles Ventura Chief Executive Officer at Ventura Solutions

Chuck Ventura is the founder and Chief Executive Officer of Ventura Solutions. He is a seasoned medical device and combination products leader with successful experience in commercialization, R&D, project management, quality, regulatory, manufacturing, and entrepreneurship. Chuck is also the co-founder and CEO of Hemotek Medical, where he is responsible for the strategic vision as well as business operations. At Hemotek, Chuck also serves as the head of regulatory and quality for all new product development, where he and his team have taken Hemotek's core product from a product napkin sketch to a commercial deal. Prior to founding Ventura Solutions, Chuck was the R&D Combination Product Systems Engineering Manager at Pfizer.

Jim Fink Chief Science Officer at Aerogen Pharma

Currently Chief Science Officer for Aerogen Pharma Corporation, San Mateo, CA. Dr. Fink serves as Adjunct Professor for the Respiratory Therapy Program at Rush Medical School in Chicago, IL, and Visiting Professor, Department of Physical therapy, Universidade Federal de Pernambuco, Recife, Brazil. Jim has a PhD in Pharmaceutical Innovation from Bradford University, UK. A respiratory therapist by training and practice, Jim was Technical Director of Respiratory Care at Medical Center UCSF for 14 years. Dr. Fink was Fellow of Respiratory Science at Nektar Therapeutics and Aerogen Ltd. developing novel aerosol delivery systems for critically ill adults and infants with more than 40 issued patents, and 200 + peer reviewed papers. He is a fellow of the International Society of Aerosols in Medicine, the American Association for Respiratory Care, and the American College of Chest Physicians. Jim was awarded the Forest M. Bird Lifetime Scientific Achievement award from the American Respiratory Care Foundation.

Carolyn Berg Vice President, Business Development at Catalent Pharma Solutions

Carolyn Berg has over 25 years of experience in pharmaceutical sales, marketing and business development. She is currently Vice President, Business Development for Catalent's inhaled drug delivery solutions where she is responsible for growing the Inhalation business in North America and Europe. Prior to Catalent, Carolyn has held various leadership roles within Cipla, Teva Respiratory and Merck, and owned her own consulting practice for pharmaceutical and healthcare clients. Carolyn holds a Bachelor of Journalism in Public Relations and a Bachelor of Arts in French from the University of Texas at Austin, and an MBA from the University of South Carolina.

Armin Braun Division Director of the Preclinical Pharmacology and Toxicology at Fraunhofer ITEMPharma Solutions

Prof. Dr. rer. nat. Armin Braun, is Division Director of the Preclinical Pharmacology and Toxicology of the Fraunhofer Institute for Toxicology and Experimental Medicine. His main focus is the preclinical development and evaluation of new drugs for airway and immune diseases. Both safety and efficacy testings are performed under highest quality standard including GLP. He is deputy head of the Fraunhofer GLP facility in Hannover. Partners are the major pharmaceutical and biotech companies from Europe, US and Japan. Therefore, he has extensive experience with animal models of immune mediated lung disease like asthma, COPD or lung infection. In addition, immunotoxicology is an important field of expertise and he is acting as work package lead in the IMI EU project ImSAVAR (Immune safety avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies). Based on his knowledge alternative in vitro and ex vivo models are developed.

John Patton Senior Strategic Advisor at Kindeva Drug Delivery

John is an entrepreneur and drug delivery scientist with extensive experience in the biotech industry and the development of new inhaled medications. Within the inhalation field, after leading the drug delivery team at Genentech (1985-1990) where he helped pioneer inhaled biologics, he founded/co-founded 4 inhalation companies: Inhale/Nektar Therapeutics in 1990, the recipient of the Wall Street Journal's Medical Innovation of the year in 2006 for Exubera, the first FDA-approved inhaled Insulin; Dance Biopharm (now Aerami Therapeutics) in 2009; InCarda Therapeutics in 2009; and iPharma Limited in 2016 (acquired by Kindeva in 2022). John has more than 110 publications and is (co)inventor of more than 50 patents.

Katharina Schwarz Head Inhalation and Aerosol Sciences at Fraunhofer Institute for Toxicology and Experimental Medicine

Dr. Katharina Schwarz heads the Department of Inhalation and Aerosol Sciences at Fraunhofer ITEM in Hannover. She oversees the aerosol/inhalation and dosimetry-related aspects in drug development programs and toxicological or inhalation exposure studies including GLP/GCP-compliance. She plays a leading role in advancing preclinical inhalation science by developing integrative, non-animal methodologies—combining ex vivo systems, in silico modeling, particle dosimetry, and aerosol pharmacokinetics—to enable early proof-of-concept predictions and inform decision-making in respiratory drug development and regulatory toxicology. Her team has developed innovative translational tools—including an inhalation-specific PBPK model and QIVIVE strategies that integrate ex vivo data—which support predictive assessments of respiratory safety and efficacy in preclinical and regulatory contexts.

Teresa Carvajal Faculty Member, Professor at the Department of Agricultural and Biological Engineering at Purdue University

Teresa Carvajal holds a faculty appointment at Purdue University in the Agricultural and Biological Engineering department, College of Agriculture and Engineering. Prior to joining Purdue University, she worked in the pharmaceutical industry for 13 years, solid, liquid and dry powder inhaler formulation development at Hoffmann-LaRoche (NJ); at Transave (NJ) formulation and characterization of inhalation aerosols; and pre-formulation activities at Bayer (CT). She has a Ph.D. in Powder Technology from the University of Bath, UK, M.S. in Physical Pharmaceutics, a minor in Physical Chemistry from the University of Arizona, USA and B.S. in Chemical Pharmaceutical Biologist from the UNAM, México. Teresa's main research interests focus on powdered biomaterials relevant to pharmaceutical, food and environmental.

David Edwards Founder Sensory Cloud, Adjunct Professor Johns Hopkins Medical School, Associate School Engineering Harvard University

David Edwards is a scientist, inventor and writer. The founder and inventor of FEND, 2020 Time Magazine Best Invention of the Year, a new daily rite for cleansing the lungs, David's inventions and startups have led to FDA-approved products on the market such as Inbrijia (inhaled L Dopa for Parkinson's). David was Professor of the Practice of Bioengineering at Harvard University in the School of Engineering & Applied Sciences from 2001 to 2019, and transitioned to Associate at the start of the pandemic to help pioneer the science and global clinical trial program of airway hydration. At Harvard, David's innovation learning programs have helped pioneer new ways of thinking about the translation of high-impact ideas as captured in his most recent book Creating Things That Matter (Holt 2018), Nautilus Book Award winner in 2018 in the category of creativity.

Loy Britto Chief Executive Officer at Healthy Airways LLC

Loy Britto is the CEO and Consultant of Healthy Airways LLC, where he advises on device components, formulations, manufacturing processes, and regulatory submissions for inhaled products. He also serves as Chief Scientific Officer at Sonohaler, driving innovation on digital connected products for inhalers. Previously, Loy spent over 30 years at GlaxoSmithKline, where he led the global MDI portfolio as Global Steward and was the subject matter expert for the Green Ventolin program. His earlier career includes senior technical roles at IBM and Atlantic Richfield Company. Loy holds a Ph.D. in Materials Engineering from MIT and is the inventor of more than a dozen patents spanning inhaled product technologies and advanced printing processes.

FROM THE IDEA TO PRODUCTION

Harro Höfliger

ALL YOU NEED

FOR HIGHER EFFICIENCY IN PROCESS DEVELOPMENT

Comprehensive and holistic service – this is part of Harro Höfliger's ALL YOU NEED claim.

Our experience – both in mechanical engineering and in pharmaceutical development and production – marks the difference that distinguishes the projects of and with Harro Höfliger. As Pharma Services, we conduct in-depth analyses that can take place at any stage of the product life cycle and help you understand all the attributes of your product. Our services extend far beyond the development of your processes and the market launch of your product.

Discover more &
get in touch:

www.hoefliger.com

Hyatt Regency San Francisco

RESCON Summit 2025 will be held at the Hyatt Regency San Francisco, a landmark 4-star hotel on the Embarcadero waterfront. Known for its striking architecture and expansive atrium, the Hyatt Regency offers a prestigious yet convenient setting for our international audience.
The hotel provides spacious, flexible meeting rooms with modern amenities, ideal for both presentations and networking. Its central location places delegates steps from the Ferry Building Marketplace and within walking distance of Union Square, Chinatown, and the city's waterfront piers. With the Embarcadero BART station just outside, guests have direct access to San Francisco International Airport and the Bay Area. The Hyatt Regency ensures a professional, well-connected, and inspiring venue for RESCON Summit 2025.

5 Embarcadero Ctr, San Francisco,
CA 94111, USA